Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Orion And Criceto Sign License Deal for APORON Spray in Parkinson’s Disease
Details : Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.
Product Name : Aporon
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 25, 2025
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement